3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Gastrointestinal
2
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Recurrence
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Interventions
venetoclax
304
Cyclophosphamide
229
Cytarabine
199
Azacitidine
187
fludarabine
180
Specimen Handling
136
Biopsy
103
fludarabine phosphate
97
Methotrexate
81
Rituximab
78
Daunorubicin
77
Dexamethasone
75
Vincristine
68
Whole-Body Irradiation
64
Mycophenolic Acid
59
Decitabine
57
Tacrolimus
55
Etoposide
52
ibrutinib
51
blinatumomab
51
Granulocyte Colony-Stimulating Factor
51
Busulfan
50
obinutuzumab
49
Prednisone
49
Melphalan
48
acalabrutinib
45
Idarubicin
45
Stem Cell Transplantation
44
Injections
44
Magnetic Resonance Spectroscopy
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Infusions, Intravenous
×
Other hematologic neoplasm
×
1 year
×
Clear all
NCT03850574
2025-08-26
TUSCANY
Aptose Biosciences Inc.
Phase 1/2
Recruiting
240 enrolled